Robert May 2024 Scaled Aspect Ratio 1200 384

Our Leadership

An open, experienced, and passionate team

At Vor Bio, leadership works seamlessly with the entire team to nurture and support free thinking, professional growth, and unconventional problem solving across departments and levels of seniority.

  • Robert Ang

    Robert Ang, MBBS, MBA

    President and Chief Executive Officer

    Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also has biotech ...

  • Updated Headshot

    Eyal Attar, MD

    Chief Medical Officer

    Eyal C. Attar, MD brings more than 20 years of demonstrated clinical excellence to his role at Vor Bio, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. Prior to joining Vor Bio, Eyal served as ...

  • Vorbiopharma Tirtha Chakraborty Sq

    Tirtha Chakraborty, PhD

    Chief Scientific Officer

    Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served ...

  • Vor Han Choi 1x1

    Han Choi, MD, LLM

    Chief Financial Officer

    Han Choi, MD, LLM brings to Vor Bio over 20 years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. Prior to joining Vor Bio, Han served as a Principal at Oracle Investment Management, Inc. ...

  • Vorbiopharma John King Sq

    John King, MBA

    Chief Commercial Officer and Head of Business Development

    John King, MBA is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor Bio, John served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra Pharma, ...

  • Vorbiopharma Tania Philip Sq

    Tania Philipp

    Chief People Officer

    Tania Philipp, Chief People Officer, brings more than 20 years of experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experienced team that will help Vor Bio achieve its ...

  • Vor Headshot1 5x7 10.19 Aspect Ratio 1 1

    David Phillips, MBA

    Senior Vice President, Head of Quality

    David Phillips has more than 28 years of extensive expertise in establishing the foundations of quality departments in multiple pharmaceutical and biotech companies. Prior to joining Vor Bio, David served as Vice President, Head of Quality at Beam Therapeutics where he built the quality management ...

  • Vor Headshot1 5x7 10.20 Aspect Ratio 1 1

    Samir Vattompadam, MS

    Senior Vice President, Portfolio Strategy and Program Management

    Samir Vattompadam brings deep cross-functional experience that spans commercial and clinical development, global-US-affiliate based roles, and small, medium, and large organizations across the pharmaceutical and biotech industry. Before joining Vor Bio, Samir served as Vice President, Program Executive for EQRx where he led cross-functional ...

President and Chief Executive Officer

Robert Ang, MBBS, MBA

Robert Ang, MBBS, MBA, is President and CEO at Vor Bio since 2019. Prior to Vor Bio, Robert gained operational experience focused on strategy and business development through roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also has biotech venture capital experience at Frazier Healthcare Ventures, where he invested in companies such as Incline Therapeutics (now Novartis) and Alnara Pharmaceuticals (now Eli Lilly), and strategy consulting experience at the Boston Consulting Group. He also has general surgery training and his clinical practice centered around soft tissue surgery with an emphasis on solid organ transplants. He received his medical degree at the University of Western Australia and has an MBA with Honors from Columbia Business School. Robert also serves as an independent director at the early-stage cancer immunotherapy company Enara Bio, a member of the Board of Directors and the Executive Committee of the Alliance for Regenerative Medicine, and a member of the Healthcare and Pharmaceutical Management Advisory Board of Columbia Business School.

Learn more about Robert’s views on the industry, the workplace, and other business topics in his CEO Perspectives blog.

 

Robert Ang

Chief Medical Officer

Eyal Attar, MD

Eyal C. Attar, MD brings more than 20 years of demonstrated clinical excellence to his role at Vor Bio, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. Prior to joining Vor Bio, Eyal served as senior vice president and CMO for Aprea Therapeutics where he led development of Aprea’s lead programs, including overseeing clinical development, pharmacovigilance, and regulatory filings. Eyal worked closely on APR-246 (eprenetapopt), a cancer therapeutic pursuing indications including myelodysplastic syndromes (MDS), AML, and various solid tumors. Before Aprea, he held multiple positions in clinical development at Agios Pharmaceuticals, including Senior Medical Director and IDH Hematology Medical Lead, where he worked on various solid tumor and hematologic malignancy programs and contributed to the successful filing of multiple INDs. Eyal has played a leadership role in all aspects of clinical development from Pre-IND through to marketing authorization for several products to treat patients with newly diagnosed and relapsed/refractory AML.

Eyal was previously an attending hematologist/oncologist at Massachusetts General Hospital focusing on leukemia, MDS, and other hematologic malignancies affecting the bone marrow. He completed fellowship training at Dana-Farber Cancer Center and residency at Brigham and Women’s Hospital. Eyal received his medical degree from the University of North Carolina School of Medicine.

Vor Headshot 5x7

Chief Scientific Officer

Tirtha Chakraborty, PhD

Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served as the Head of Hematology at CRISPR Therapeutics, leading research on hemoglobin disorders. His team’s work on autologous cell therapy using gene edited hematopoietic stem cells paved the way to the first approved CRISPR engineered product, Casgevy, a treatment for Sickle Cell Disease. Before that, Tirtha built the mRNA platform at Moderna Therapeutics. In his academic life, he was trained as a molecular geneticist and focused on the role of small RNAs in lymphocyte development and lymphomagenesis in the laboratory of Professor Klaus Rajewsky at Harvard Medical School. Tirtha’s PhD thesis was on deciphering the molecular mechanism of naturally acquired immunity against the malarial parasite Plasmodium falciparum. Tirtha serves as a Scientific Advisory Board Member of Specific Biologics, a genome editing company, and as a Board Member and Scientific Advisory Board Member of the Belgium based DROIA Venture company, Vedra Therapeutics, focused on mitochondrial genome editing and delivery. In addition to his CSO responsibilities, he also oversees Technical Operations at Vor Bio.

Tirtha Chakraborty

Chief Financial Officer

Han Choi, MD, LLM

Han Choi, MD, LLM brings to Vor Bio over 20 years of experience in public and private investment management, business development, and corporate strategy within the pharmaceutical and biotechnology industry. Prior to joining Vor Bio, Han served as a Principal at Oracle Investment Management, Inc. until September 2024, where he managed its healthcare public and private equity portfolios. For over two decades at Oracle, Han was responsible for sourcing, negotiating, and managing investments in the pharmaceutical and biotechnology sectors and provided strategic advice to portfolio companies on clinical, business development, and capital market strategies. Prior to joining Oracle, he held positions of increasing responsibility in licensing and business development at Pharmacia Corporation and Bristol-Myers Squibb Company. Han received his M.D. from The Mount Sinai School of Medicine and holds law degrees from Harvard Law School, and Oxford University. He is also a licensed physician in New York State and a member of the New York State Bar, Third Judicial Department.

Vor Han Choi 5x7

Chief Commercial Officer and Head of Business Development

John King, MBA

John King, MBA is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor Bio, John served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra Pharma, John led the organization in preparing for a global commercial launch. Prior to Ra Pharma, he was Vice President, U.S. Neurology Business Unit, at Alexion Pharmaceuticals where he was responsible for building and leading the team that launched Soliris® (eculizumab) for gMG. At Alexion, he also served roles of increasing responsibility, including Vice President, Head of Global LAL-D Franchise and Vice President, Head of Global Hematology Franchise. Before joining Alexion in 2009, John served in commercial roles of increasing responsibility at Wyeth Pharmaceuticals, including Product Director of Enbrel® (etanercept). He began his career at Ernst & Young LLP. John obtained his B.S. in business logistics and MBA from the Pennsylvania State University.

Vorbiopharma John King 5x7

Chief People Officer

Tania Philipp

Tania Philipp, Chief People Officer, brings more than 20 years of experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experienced team that will help Vor Bio achieve its objectives. Tania has a passion for creating a collaborative company culture and for fostering team dynamics that support individual and organizational growth. Prior to joining Vor Bio, she was Vice President and Head of Human Resources at Tango Therapeutics, where she was responsible for developing and implementing the strategic human resources vision that supported the company’s objectives and defined its culture. Before Tango, Tania held various senior human resources positions for a number of companies, including Bavarian Nordic, Mendel Biotechnology, Sunesis Pharmaceuticals, Pearl Therapeutics (acquired by AstraZeneca), and Protein Design Labs. Tania holds a master’s degree in behavioral psychology from The University of the Pacific.

Tania Philip

Senior Vice President, Head of Quality

David Phillips, MBA

David Phillips has more than 28 years of extensive expertise in establishing the foundations of quality departments in multiple pharmaceutical and biotech companies. Prior to joining Vor Bio, David served as Vice President, Head of Quality at Beam Therapeutics where he built the quality management system from the ground up, spanning all GxP areas. He also served as Vice President, Head of Quality at Kiniksa Pharmaceuticals where he established the company’s overall strategic long-term vision for quality. Before Kiniksa, David was Vice President, Quality at Shire Pharmaceuticals prior to its acquisition by Takeda. Notably, David was a core member of the team responsible for the integration of a number of programs and companies acquired by Shire and was responsible for various aspects of quality product lifecycle planning, quality aspects of geographic expansion, and technical oversight of key quality functions across a network of more than 25 locations.

David’s experience working outside of the United States – at Lonza Biologics in Singapore and at VaxGen, Inc./Celltrion in South Korea– provides him with a valuable global perspective. While at Lonza, he helped establish the country’s first biologics manufacturing park. David holds an MBA in new product development and project management and a Bachelor of Science in biochemistry and polymer chemistry from the North Carolina State University.

David Phillips, MBA

Senior Vice President, Portfolio Strategy and Program Management

Samir Vattompadam, MS

Samir Vattompadam brings deep cross-functional experience that spans commercial and clinical development, global-US-affiliate based roles, and small, medium, and large organizations across the pharmaceutical and biotech industry. Before joining Vor Bio, Samir served as Vice President, Program Executive for EQRx where he led cross-functional program strategy teams, including external partners, for lead candidates in immuno-oncology from late-stage studies through to regulatory submissions, including the company’s first marketing authorization applications to the MHRA and EMA for Sugemalimab in metastatic non-small cell lung cancer. Prior to EQRx, he was Executive Director, Product Team Leader at Seagen for several late-stage ADCs including TIVDAK, PADCEV, and ADCETRIS and collaborated with development partners at Genmab, Astellas, and Takeda. Samir led cross-functional teams focusing on the development, submission, and approval for TIVDAK in metastatic cervical cancer. Earlier in his career, Samir served at Roche in various roles including the Global Commercial Director for GU cancers for TECENTRIQ (atezolizumab), Global Product Manager for GAZYVA (obinutuzumab) in lymphomas, and roles spanning oncology marketing, sales, and medical affairs at Roche Canada. Samir holds a Masters in Medical Sciences and a Bachelor of Science in Biology from McMaster University.

Samir Vattompadam

From the Vor Bio team

“The leadership team at Vor leads by example. They bring their authentic selves in the office, they attend company events, and they interact with everyone at every level of the company. They truly care about the people here and making the best experience for everyone.”

Janet Gee
Associate Director
Financial Planning and Analysis

“We have access to all of our executives, which is a huge advantage. They truly take an interest in helping employees grow, learn and develop. This genuine mentorship is something that makes Vor stand out.”

Lee Schwartz
Director
Human Resources

Join The Vor Bio team

Collaborate
to change
the world

Join a passionate team advancing the science and shaping the future of cancer treatments.

Board of Directors

Our Board members offer expert global biopharma experience and perspective.